You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 5,093,261

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,093,261

Title:	Cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins
Abstract:	A new human/human fused cell clone derived from human B cells having the ability to produce immunoglobulins and human B cells substantially lacking the ability to produce immunoglobulins, antigen-specific human immunoglobulins produced by the human/human fused cell clone, and a method of producing the human immunoglobulins. More specifically, a human/human hybridoma having the ability to produce antigen-specific human immunoglobulins, which is a human/human fused cell strain derived from human B cells of a human patient with liver cancer and a subclone of a human lymphoblast cell strain; and antigen-specific human immunoglobulins produced by the human/human fused cell strain.
Inventor(s):	Hagiwara; Hideaki (Kasai-shi, Hyogo-ken, JP), Nagao; Junzo (Kasai, JP)
Assignee:	Hagiwara; Yoshihide (Kasai, JP) Hagiwara; Hideaki (Kasai, JP)
Application Number:	07/196,610
Patent Claims:	1. The antigen-specific human immunoglobulin which is produced by human/human hybridoma TOH/B9 FERM BP-1883 and which has the following biochemical properties: (a) it is human immunoglobulin (IgA), and (b) it specifically binds to human cell line PLC/PRF/5 (Alexander cells) derived from human liver cancer. 2. The antigen-specific human immunoglobulin which is produced by human/human hybridoma TOH/D5 FERM BP-1882 and which has the following biochemical properties: (a) it is human immunoglobulin G (IgG), and (b) it specifically binds to human cell line PLC/PRF/5 (Alexander cells) or a human liver cancer tissue. 3. A human/human hybridoma TOH/B9 FERM BP-1883 which produces antigen-specific human immunoglobulin, said hybridoma being a human/human fused cell strain derived from a human B cell taken from a human patient with liver cancer and a subclone of a human lymphoblast cell strain. 4. A human/human hybridoma TOH/D5 FERM-BP-1882 which produces antigen-specific human immunoglobulin, said hybridoma being a human/human fused cell strain derived from a human B cell taken from a human patient with liver cancer and a subclone of a human lymphoblast cell strain. 5. The human/human hybridoma of claim 3 which has the following cytobiochemical properties (1) to (5): (1) it secretes (produces) a human immunoglobulin A (IgA), (2) it has a doubling time of about 37 hours, (3) it has a DNA content about twice as large as that of a normal human lymphocyte, (4) the IgA mentioned in (1) above shows bindability to human cell line PLC/PRF/5 (Alexander cells) (derived from human liver cancer), and (5) it can be divided and proliferated in a medium containing hypoxanthine, amethopterin, thymidine and ouabain. 6. The human/human hybridoma of claim 4 which has the following cytobiochemical properties (1) to (5): (1) it secretes (produces a human immunoglobulin G (IgG), (2) it has a doubling time of about 37 hours, (3) it has a DNA content about twice as large as that of a normal human lymphocyte, (4) the IgG mentioned in (1) above shows bindability to human cell line PLC/PRF/5 (Alexander cells) or a human liver cancer tissue, and (5) it can be divided and proliferated in a medium containing hypoxanthine, amethopterin, thymidine and ouabain. 7. The antigen-specific human immunoglobulin of claim 4 or 5, wherein said immunoglobulin is bound to an agent selected from the group consisting of a chemotherapeutic agent, interferon, high-molecular weight toxin, anti-cancer drug-containing liposome, and radioactive x-ray sensitive agent.

Details for Patent 5,093,261

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Csl Behring Ag	CARIMUNE, CARIMUNE NF, PANGLOBULIN, SANDOGLOBULIN	immune globulin intravenous (human)	For Injection	102367	07/27/2000	⤷ Try a Trial	2009-03-03
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	07/26/2007	⤷ Try a Trial	2009-03-03
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	10/02/2009	⤷ Try a Trial	2009-03-03
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.